Singulary - instructions for use, analogs, reviews and release forms (5 mg and 10 mg tablets, 4 mg chewable) medicines for the treatment of bronchial asthma and allergic rhinitis in adults, children and in pregnancy
In this article, you can read the instructions for using the drug Singular. There are reviews of visitors to the site - consumers of this medication, as well as opinions of doctors of specialists on the use of Singular in their practice. A big request is to actively add their feedback on the drug: the medicine helped or did not help get rid of the disease, which were observed complications and side effects, possibly not declared by the manufacturer in the annotation. Analogs of the Singular if there are existing structural analogues. Use for the treatment of bronchial asthma and allergic rhinitis in adults, children, as well as during pregnancy and lactation.
Singular antagonist of leukotriene receptors. The singular selectively inhibits the CysLT1 receptors of cysteinyl leukotrienes (LTC4, LTD4, LTE4) of the respiratory tract epithelium, and also prevents the bronchospasm caused by the inhalation of cysteinyl leukotriene LTD4 in patients with bronchial asthma. A dose of 5 mg is sufficient to stop the bronchospasm induced by LTD4. Application in doses exceeding 10 mg once a day does not improve the effectiveness of the drug.
The Singular causes bronchodilation within 2 hours after ingestion and may supplement the bronchodilation caused by beta2-adrenomimetics.
Composition
Montelukast + auxiliary substances.
Pharmacokinetics
After ingestion, the Singular is quickly and almost completely absorbed from the digestive tract. Bioavailability with ingestion is 64%. Montelukast is actively metabolized in the liver. When used in therapeutic doses, the concentration of metabolites of montelukast in plasma in an equilibrium state in adults and children is not determined. After oral administration of montelukast, 86% is excreted with feces for 5 days and less than 0.2% with urine, which confirms that montelukast and its metabolites are excreted almost exclusively with bile.
When taking montelukast in the morning and evening hours, there is no difference in pharmacokinetics.
The pharmacokinetics of montelukast in women and men has a similar character.
Since montelukast and its metabolites are not excreted in the urine, the pharmacokinetics of montelukast in patients with renal insufficiency have not been evaluated. Correction of dose in this category of patients is not required.
Indications
Prophylaxis and long-term treatment of bronchial asthma in adults and children aged 6 years and older, including:
- prevention of day and night symptoms of the disease;
- treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid;
- prevention of bronchospasm caused by physical exertion;
- relief of daytime and nighttime symptoms of seasonal allergic rhinitis (in adults and children 6 years of age and older) and persistent allergic rhinitis (in adults and children 6 years and older).
Forms of release
The tablets covered with a cover of 10 mg.
Tablets chewing 5 mg and 4 mg.
Instructions for use and reception scheme
Film-coated tablets
The drug is taken orally 1 time per day, regardless of food intake. To treat bronchial asthma, Singular should be taken in the evening.In the treatment of allergic rhinitis, the drug can be taken at any time of the day. With a combined pathology (bronchial asthma and allergic rhinitis), the drug should be taken in the evening.
Adults and adolescents aged 15 years and older are prescribed a dose of 10 mg (1 tablet, coated) per day.
Tablets, chewing
Inside 1 time per day, regardless of food intake.
For treatment of bronchial asthma, the Singular preparation should be taken in the evening.
In the treatment of allergic rhinitis drug can be taken at any time of the day at the request of the patient.
Patients with bronchial asthma and allergic rhinitis should take 1 tablet of Singular once a day in the evening.
Children aged 6 to 14 years are prescribed a dose of 5 mg (1 tablet chewing) per day. The choice of dose for this age group is not required.
Children aged 2 to 5 years are prescribed a dose of 4 mg (1 tablet chewing) per day.
General recommendations
The therapeutic effect of the Singular preparation on the indicators reflecting the course of bronchial asthma develops during the first day. The patient should continue to take the Singular as in the period of achieving control over the symptoms of bronchial asthma, and during periods of exacerbation of bronchial asthma.
For elderly patients, patients with renal insufficiency, as well as patients with mild or moderate liver function disorders, and also depending on gender, a special dose selection is not required.
Purpose of the preparation Singular at the same time as other types of treatment for bronchial asthma
The Singular preparation can be added to the treatment of the patient with bronchodilators and inhaled glucocorticosteroids (GCS).
Side effect
- anaphylaxis;
- angioedema;
- rash;
- itching;
- hives;
- unusual bright dreams;
- hallucinations;
- drowsiness;
- irritability;
- Excitement (including aggressive behavior);
- fatigue;
- headache;
- suicidal thoughts and suicidal behavior (suicidal);
- insomnia;
- convulsive seizures;
- nausea, vomiting;
- diarrhea;
- stomach ache;
- arthralgia;
- Myalgia, including muscle cramps;
- nodular erythema;
- tendency to increase bleeding, subcutaneous hemorrhage;
- palpitation;
- edema.
Contraindications
- children under 6 years (for coated tablets), up to 2 years (for chewing tablets);
- hypersensitivity to the components of the drug.
Application in pregnancy and lactation
Singular should be used during pregnancy and lactation only in cases where the expected benefit for the mother exceeds the potential risk to the fetus or the baby.
Use in children
Contraindicated in the form of chewable tablets for children under 2 years old, for coated tablets - before the age of 6 years.
For children aged 2 to 5 years with bronchial asthma and / or allergic rhinitis, the dose is 4 mg (1 chewable tablet) per day.
Children aged 6 to 14 years are prescribed a dose of 5 mg (1 chewable tablet) per day. The choice of dose for this age group is not required.
Application in elderly patients
For elderly patients, no special dose selection is required.
special instructions
Singular is not recommended for the treatment of acute attacks of bronchial asthma. In the acute course of bronchial asthma, patients should be prescribed medications for the treatment, stopping and preventing the onset of the disease.
The dose of concomitantly with the preparation Singular of inhaled glucocorticosteroids can be gradually reduced under the supervision of a doctor. Do not dramatically replace the drug Singular therapy with inhaled or oral GCS.
A decrease in the dose of GCS for systemic administration in patients receiving antiasthmatic drugs, including leukotriene receptor antagonists, was rarely accompanied by the appearance of one or more of the following: eosinophilia, hemorrhagic rash, exacerbation of pulmonary symptoms, cardiac complications and / or neuropathy, sometimes diagnosed as a syndrome of Charge-Straus (systemic eosinophilic vasculitis). Although the causal relationship of these adverse events with therapy with leukotriene receptor antagonists has not been established, care should be taken when observing a reduction in the systemic dose of GCS in patients receiving Singular, and appropriate clinical monitoring is performed.
Influence on the ability to manage motor vehicles and work with mechanisms
Data suggesting that the administration of the drug Singular affects the ability to drive or move vehicles is not detected.
Drug Interactions
The singular can be prescribed together with other drugs traditionally used for the prevention and long-term treatment of bronchial asthma.Montelukast at the recommended clinical dose had no clinically significant effect on the pharmacokinetics of the following drugs: theophylline, prednisone, prednisolone, oral contraceptives (ethinyl estradiol / norethindrone 35/1), terfenadine, Digoxin and warfarin.
In patients who simultaneously received phenobarbital, the AUC of montelukast decreased by about 40%. Selection of a dose of Singular for this category of patients is not required.
If the bronchodilators are ineffective as a monotherapy for bronchial asthma, a singularity can be added to the treatment. When the therapeutic effect (usually after the first dose) is reached, the dose of bronchodilators can be gradually reduced against the background of therapy with the Singular preparation.
Treatment with Singular provides an additional therapeutic effect in patients receiving inhaled glucocorticosteroids. At achievement of stabilization of a status of the patient reduction of a dose of GCS is possible. The dose of GCS should be reduced gradually, under the supervision of a doctor. In some patients, the intake of inhaled glucocorticosteroids can be completely abolished. It is not recommended to sharply replace inhaled glucocorticosteroids with Syngular.
Analogues of the medicinal product Singular
Structural analogs for the active substance:
- Moncast;
- Montelukast sodium amorphous;
- Singlon;
- Singularus.
Similar medicines:
Other medicines:
- Roaccutane - instructions for use, analogs, reviews and release forms (capsules or tablets 10 mg and 20 mg) of a drug for the treatment of acne or acne in adults, children and pregnancy. Composition
- Lactobacterin - instructions for use, reviews, analogs and forms of release (tablets, vaginal suppositories 5 doses, dry powder for the preparation of a solution) drug for the treatment of dysbiosis in adults, children and pregnancy
- Premoderation of reviews to medicines